NewKerala.com

TB's Secret Armor: How Bacteria Shield Themselves from Antibiotics

A new study from IIT Bombay has cracked a major mystery in the fight against Tuberculosis. Researchers found that TB bacteria aren't just mutating to resist drugs; they're physically changing their outer fat coating to block antibiotics. This shield is especially strong when the bacteria are dormant, making them incredibly hard to kill. The discovery points to a new strategy: combining existing drugs with compounds that weaken this bacterial armor.

Key Points: IIT Bombay Study Reveals How TB Bacteria Resist Antibiotics

  • Study shows dormant TB bacteria need 2-10 times more drug to stop growth
  • Researchers identified over 270 distinct lipid molecules in bacterial membranes
  • Dormant cells have rigid outer membranes that block antibiotic entry
  • Weakening the membrane could make existing TB drugs effective again
3 min read

IIT Bombay study shows how TB bacteria shield themselves from antibiotics, stay alive longer

IIT Bombay research uncovers how TB bacteria alter their outer membrane to block antibiotics, offering new strategies to combat drug tolerance and persistent infections.

"The rigid outer layer becomes the main barrier. It is the bacterium’s first and strongest line of defence. - Prof. Shobhna Kapoor, IIT Bombay"

New Delhi, Dec 3

The bacteria Mycobacterium tuberculosis, which causes the world’s most infectious disease Tuberculosis (TB), can survive antibiotic treatment and live longer by changing their outer fat coating, according to a new study led by researchers from the Indian Institute of Technology (IIT) Bombay on Wednesday.

Even with effective antibiotics and widespread vaccination campaigns, TB continues to take lives.

Globally, 10.7 million people developed TB and 1.23 million died from the disease in 2024, while India carries one of the highest burdens -- over 2.71 million cases in 2024.

In the study, published in the Chemical Science journal, the researchers showed that the key to the bacteria's drug tolerance lies in their membranes -- complex barriers made mostly of fats, or lipids that protect the cell.

The team grew the bacteria under two conditions: an active phase, when the bacteria were dividing rapidly as they do in an active infection, and a late stage mimicking dormancy, as seen in latent infections.

When they exposed the bacteria to four common TB drugs: rifabutin, moxifloxacin, amikacin, and clarithromycin, the team found that the concentration of drugs needed to stop 50 per cent of bacterial growth was two to 10 times higher in dormant bacteria than in active ones.

In other words, “the same drug that worked well in the early stage of the disease would now be needed at a much higher concentration to kill the dormant/persistent TB cells. This change was not caused by genetic mutations, which usually explain antibiotic resistance,” said Prof. Shobhna Kapoor from the Department of Chemistry, IIT-B.

Lack of mutations associated with antibiotic resistance in the bacteria confirmed that the reduced drug sensitivity could be linked to the bacteria’s dormant state and most likely their membrane coats rather than genetic changes.

Further, the team identified more than 270 distinct lipid molecules in the bacterial membranes, which showed clear differences between active and dormant cells.

While the active bacteria had loose, fluid membranes, the dormant ones had rigid, tightly ordered structures, indicating its defence mechanism.

“People have studied TB from the protein point of view for decades,” said Kapoor.

“But lipids were long seen as passive components. We now know they actively help the bacteria survive and resist drugs,” she added.

Next, the team found that the antibiotic rifabutin could easily enter active cells but barely crossed the outer membrane of dormant ones.

“The rigid outer layer becomes the main barrier. It is the bacterium’s first and strongest line of defence,” explained Kapoor.

If the outer membrane blocks antibiotics, weakening it could make the drugs work better.

“Even old drugs can work better if combined with a molecule that loosens the outer membrane,” said Kapoor, noting that the approach makes bacteria sensitive to the drugs again without giving them a chance to develop permanent resistance.

- IANS

Share this article:

Reader Comments

R
Rohit P
Over 2.7 million cases in India alone... that number is heartbreaking. My cousin had to go through the full TB treatment, it was so hard on him. Research like this gives real hope. If we can make the current drugs more effective, it could save countless lives and reduce the treatment burden on patients.
A
Aman W
Fascinating study. It shows how clever these pathogens are—changing their "armor" instead of their genes. A respectful critique though: while the lab findings are promising, the real test is translating this to a clinical setting that works in our public health system. Cost and accessibility will be key.
P
Priya S
"Lipids were long seen as passive components." This is why fundamental research is so important! We keep discovering new layers of complexity in biology. Big congratulations to Prof. Kapoor and her team. More funding should go to such innovative work in our own institutes.
D
David E
Working in global health, I see the TB burden firsthand. A breakthrough in understanding dormancy and persistence is huge. The global numbers are staggering. If this "membrane weakening" adjuvant strategy works, it could be a game-changer for treatment regimens worldwide, not just in India.
K
Kavya N
This makes so much sense! Bacteria going into a dormant, rigid state to survive harsh conditions... nature's resilience is scary. Proud that our scientists are at the forefront of cracking this puzzle. Jai Hind! 🙏 Now, let's ensure the benefits reach the people who need it most in our villages and towns.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50